Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Fiona Watt wins prestigious Michael Mason Prize 2016.

Dr Fiona Watt, of the Kennedy Institute of Rheumatology is the winner of the prestigious Michael Mason Prize 2016 awarded by the British Society for Rheumatology, for her contributions to the field.

The award represents the increasing interest in osteoarthritis research in recent years and desire to find new ways to treat the disease: osteoarthritis remains the leading cause of joint pain and disability in the UK, and major reason for joint replacement.
- Dr Fiona Watt

Fiona is a Senior Clinical Research Fellow at NDORMS, as well as an honorary consultant rheumatologist at the Nuffield Orthopaedic Centre. Her research work focuses on human clinical studies and trials relevant to osteoarthritis within the Arthritis Research UK Centre for Osteoarthritis Pathogenesis, where she also leads the Clinical Translation theme.

Her research interest is in the early diagnosis, stratification and treatment of osteoarthritis and she is involved with a number of groups and steering committees which focus on the treatment of this condition.

Speaking of her award, Fiona says: "It is a great honour to be this year's recipient of the Michael Mason prize. The award represents the increasing interest in osteoarthritis research in recent years and desire to find new ways to treat the disease: osteoarthritis remains the leading cause of joint pain and disability in the UK, and major reason for joint replacement. Joint injury is the single greatest risk factor for developing osteoarthritis, which often affects people in mid-life.

"Our work relating to the responses of joint tissues to injury and subsequently in individuals with recent joint injury represents work over many years by myself and colleagues at the Kennedy Institute for Rheumatology. By testing discoveries from the laboratory in clinical studies, we aim to find better of ways of predicting the onset of arthritis, and developing medical treatments which can slow or prevent arthritis, and improve joint pain for people with the condition".

The Michael Mason Prize is awarded by the Heberden Committee for excellence in clinical or scientific research in the field of rheumatology. Dr Michael Mason was a renowned clinical rheumatologist, qualified from Oxford and St Bartholomew's Hospital London. His practice was in the wider aspects of rheumatology and together with Dr W S Tegner he established an associated academic professorial unit in Rheumatology in the University of London at the London Hospital Medical College. Additionally he was instrumental in the development of the Bone and Joint Research at the London Hospital Medical College.

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).